First Ascent Biomedical Inc., a clinical-stage functional precision medicine company advancing the novel xDRIVE (Ex Vivo Drug Response Identification and Validation Engine) functional precision medicine AI platform announced today that it will present two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL.
The presentations will highlight the Company’s currently enrolling personalized medicine trials for childhood and adult cancer patients, as well as novel findings resulting from the Company’s explainable AI multi-omics biomarker development platform.
Poster Details
Abstract Number: 1551 | Poster Bd #: 422
Title: Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric and adult cancers.
Session Type and Title: Poster Presentation; Care Delivery/Models of Care
Session Date and Time: June 1, 2024, 9:00 AM – 12:00 PM CDT
Abstract Number: 10061 | Poster Bd #: 428
Title: Biomarker development from functional precision medicine datasets via explainable machine learning.
Session Type and Title: Poster Presentation; Pediatric Cancer
Session Date and Time: June 1, 2024, 1:30 PM – 4:30 PM CDT
The poster presentations will be available First Ascent’s website at FirstAscentBiomedical.com, following ASCO.
About First Ascent Biomedical
First Ascent Biomedical, a clinical-stage functional precision medicine company, is advancing the novel xDRIVE (Ex Vivo Drug Response Identification and Validation Engine) functional precision medicine AI platform. This platform combines groundbreaking advancements in functional drug sensitivity testing and patient tumor modeling with explainable artificial intelligence/machine learning to provide personalized treatment options to cancer patients in with actionability and accuracy beyond any platform available today, all in under two weeks.
Headquartered in Miami, Florida, we are led by an experienced management team dedicated to the mission of bringing personalized cancer treatments to patients with the greatest need. First Ascent’s leadership combines experienced Fortune 250 leadership with deep expertise in molecular biology, biochemistry, artificial intelligence, machine learning, and drug development.
For more information please visit FirstAscentBiomedical.com and follow us LinkedIn.